Potential bias in ophthalmic pharmaceutical clinical trials
Paul VarnerJohn J Pershing Veterans’ Administration Medical Center, Poplar Bluff, Missouri, USAAbstract: To make clinicians aware of potential sources of error in ophthalmic pharmaceutical clinical trials that can lead to erroneous interpretation of results, a critical review of the st...
Guardado en:
Autor principal: | Paul Varner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/12c8bb65eba64033ac521bbd993f403b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of difluprednate ophthalmic emulsion in clinical practice
por: Karim N Jamal, et al.
Publicado: (2009) -
Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
por: Daoud Al-Badriyeh, et al.
Publicado: (2010) -
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
por: Cervantes LJ, et al.
Publicado: (2011) -
Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
por: Meerovitch K, et al.
Publicado: (2013) -
Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh S
Publicado: (2015)